Recipharm

Recipharm

Recipharm is a contract development and manufacturing organisation (CDMO).

Financials

Estimates*

Edit
Revenues, earnings & profits over time
SEK2016201720182019202020212022
Revenues4.6b5.4b6.4b7.5b11.1b11.7b12.3b
% growth25 %18 %19 %17 %49 %5 %5 %
EBITDA727m730m994m1.1b1.8b2.2b2.4b
% EBITDA margin16 %14 %16 %15 %16 %19 %19 %
Profit-(171m)159m343m339m571m701m
% profit margin-(3 %)2 %5 %3 %5 %6 %
EV / revenue-1.8x1.8x1.9x2.8x--
EV / EBITDA-13.2x11.5x12.7x17.4x--

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO

SEK1.5b

Post IPO Debt
N/A

$32.0m

Post IPO Equity
Total Funding-

Recent News about Recipharm

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Recipharm

Edit
GenIbet Biopharmaceuticals
ACQUISITION by Recipharm Feb 2022
Lusomedicamenta
ACQUISITION by Recipharm Nov 2014
MITIM
ACQUISITION by Recipharm Feb 2016
Corvette Group Pharmaceutical Services
ACQUISITION by Recipharm Aug 2014
Vibalogics
ACQUISITION by Recipharm Feb 2022
Cirrus Pharmaceuticals
ACQUISITION by Recipharm Apr 2016
Nitin Lifesciences
ACQUISITION by Synokem Pharmaceuticals Dec 2023
Arranta Bio
ACQUISITION by Recipharm Feb 2022